TickerStar monitors official filings, investor releases, earnings, and call updates for BIAF. Subscribe to BIAF alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.
bioAffinity Technologies held a Special Meeting on November 20, 2026 where stockholders approved five proposals, including a charter amendment to decrease authorized common shares from 350,000,000 to 200,000,000 shares. The meeting also approved warrant exercise proposals related to private placement offerings that closed in August and October 2026, as well as an offering proposal for non-public offerings under Nasdaq Marketplace Rule 5635(d).
No financial results were reported, so there is no beat, miss, or in-line comparison with the supplied FY2026 guidance. bioAffinity reported 235 CyPath Lung tests performed in October 2026, up 29% from October 2025, and said the volume was the highest monthly level for the test. October volume was approximately 45% of all tests performed in Q3 2026.
bioAffinity Technologies reported Q3 2026 revenue of $1.07 million, down 26% year-over-year from $1.45 million in Q3 2025, due primarily to decreased average reimbursement per CyPath Lung test. The company reported a net loss of $5.28 million compared to a net loss of $5.05 million in the prior-year quarter. Cash and cash equivalents were $2.55 million as of September 30, 2026, down from $6.45 million at December 31, 2025.
BIAF filed its 10-Q; the most relevant disclosure change is unchanged Going concern assessment: Management concludes substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from issuance date given $2.6M cash on hand and expected operating expenditures.
bioAffinity Technologies (NASDAQ: BIAF) entered a definitive agreement with an institutional investor to sell shares of common stock (or pre-funded warrants in lieu thereof) at $6.122 per share ($6.115 per pre-funded warrant) in a registered direct offering priced at-the-market under Nasdaq rules, plus a concurrent private placement of warrants to purchase up to 980,072 shares at $6.122 per share. Gross proceeds are expected to be approximately $4 million before placement agent fees and other expenses, with clos...
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) closed a previously announced registered direct offering of common stock (or pre-funded warrants in lieu thereof) with an institutional investor at a purchase price of $6.122 per share ($6.115 per pre-funded warrant), priced at-the-market under Nasdaq rules. The Company concurrently closed a private placement of warrants to purchase up to 980,072 shares of common stock at an exercise price of $6.122 per share, exercisable following stockholder approval and exp...
On October 8, 2026, bioAffinity Technologies entered into a securities purchase agreement with an institutional investor for a registered direct offering of 116,545 shares of common stock at $6.122 per share and pre-funded warrants for 536,836 shares at $6.115 per pre-funded warrant, together with a concurrent private placement of unregistered warrants for an aggregate 980,072 shares at an exercise price of $6.122 per share. Gross proceeds are expected to be approximately $4 million before placement agent fees a...